Immune Design Corp. Daily Stock Analysis

Daily Stock Analysis, IMDZ, Immune Design Corp, priceseries

Immune Design Corp. Daily Stock Analysis
Stock Information
Open
5.84
Close
5.85
High
5.85
Low
5.84
Previous Close
5.85
Daily Price Gain
0.00
YTD High
5.85
YTD High Date
Apr 1, 2019
YTD Low
1.22
YTD Low Date
Jan 3, 2019
YTD Price Change
4.52
YTD Gain
339.85%
52 Week High
5.85
52 Week High Date
Apr 1, 2019
52 Week Low
1.10
52 Week Low Date
Dec 24, 2018
52 Week Price Change
2.10
52 Week Gain
56.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 9. 2017
5.90
Mar 24. 2017
6.48
11 Trading Days
9.86%
Link
LONG
May 18. 2017
6.70
May 31. 2017
7.23
8 Trading Days
7.84%
Link
LONG
Jun 15. 2017
7.15
Jul 5. 2017
9.29
13 Trading Days
29.89%
Link
LONG
Jul 21. 2017
9.95
Jul 31. 2017
10.45
6 Trading Days
5.03%
Link
LONG
May 9. 2018
3.75
Jun 4. 2018
4.35
17 Trading Days
15.89%
Link
LONG
Nov 29. 2018
1.48
Dec 13. 2018
1.71
9 Trading Days
15.41%
Link
Company Information
Stock Symbol
IMDZ
Exchange
NasdaqGM
Company URL
http://www.immunedesign.com
Company Phone
(206) 682-0645
CEO
Carlos V. Paya
Headquarters
Washington
Business Address
1616 EASTLAKE AVE. E, SUITE 310, SEATTLE, WA 98102
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001437786
About

Immune Design Corp. is a clinical-stage immunotherapy company, which focuses on cancer with next-generation in vivo approaches designed to enable the body's immune system to fight disease. It includes products candidates from discovery platforms, IMDZVe or ZVex, and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.

Description

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo immunotherapy treatments. It develops various product candidates based on its ZVex and GLAAS product discovery platforms. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma. In addition, its technologies are also used in the fields of infectious diseases and allergies. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; a collaboration agreement with Sanofi Pasteur; and a clinical collaboration with Gritstone Oncology. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading